Mondrian Investment Partners LTD Has $926,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mondrian Investment Partners LTD boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 12,173 shares of the biopharmaceutical company’s stock after buying an additional 568 shares during the quarter. Mondrian Investment Partners LTD’s holdings in Gilead Sciences were worth $926,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Gilbert & Cook Inc. raised its holdings in Gilead Sciences by 5.3% during the fourth quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock worth $550,000 after acquiring an additional 344 shares in the last quarter. Aveo Capital Partners LLC boosted its holdings in shares of Gilead Sciences by 8.6% in the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock valued at $443,000 after buying an additional 435 shares during the last quarter. Jump Financial LLC grew its stake in shares of Gilead Sciences by 141.2% in the fourth quarter. Jump Financial LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $579,000 after buying an additional 4,184 shares in the last quarter. TrinityPoint Wealth LLC grew its stake in shares of Gilead Sciences by 2.9% in the fourth quarter. TrinityPoint Wealth LLC now owns 5,708 shares of the biopharmaceutical company’s stock valued at $462,000 after buying an additional 159 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Gilead Sciences by 1.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 377,868 shares of the biopharmaceutical company’s stock worth $30,611,000 after buying an additional 4,745 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Thursday, June 20th. Evercore ISI upgraded Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Truist Financial raised their price target on Gilead Sciences from $82.00 to $83.00 and gave the company a “hold” rating in a report on Thursday, August 15th. Finally, Royal Bank of Canada increased their price objective on shares of Gilead Sciences from $72.00 to $74.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 4th. Twelve equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $82.06.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the transaction, the insider now owns 114,979 shares in the company, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,847 shares of company stock valued at $3,002,940. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 0.1 %

GILD opened at $83.05 on Wednesday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company’s 50 day moving average price is $76.09 and its two-hundred day moving average price is $71.00. The firm has a market capitalization of $103.47 billion, a price-to-earnings ratio of 230.69, a PEG ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The firm had revenue of $6.95 billion during the quarter, compared to analyst estimates of $6.64 billion. As a group, research analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Shareholders of record on Friday, September 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.71%. Gilead Sciences’s payout ratio is currently 855.56%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.